|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/15 Bionik Laboratories Corp. 10-K 12/31/14 48:1.6M Walker Jody M/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 273K
2: EX-14.1 Code of Ethics -- exhibit141 HTML 60K
3: EX-21 Exhibit 21.1 HTML 15K
4: EX-31 Certification -- §302 - SOA'02 -- exhibit31 HTML 24K
5: EX-32 Certification -- §906 - SOA'02 -- exhibit32 HTML 21K
31: R1 Document and Entity Information HTML 47K
24: R2 Bionik Laboratories Corp. (f/k/a Drywave HTML 63K
Technologies, Inc.) Consolidated Balance Sheets
29: R3 Bionik Laboratories Corp. (f/k/a Drywave HTML 42K
Technologies, Inc.) - Consolidated Balance Sheets
(Parantheticals)(Usd $)
33: R4 Bionik Laboratories Corp. (f/k/a Drywave HTML 50K
Technologies, Inc.) - Consolidated Statements of
Operations
44: R5 Bionik Laboratories Corp. (f/k/a Drywave HTML 37K
Technologies, Inc.) - Consolidated Statement of
Changes in Stockholders' Equity (Deficit) For the
Years Ended December 31, 2014 and 2013
25: R6 Bionik Laboratories Corp. (f/k/a Drywave HTML 54K
Technologies, Inc.) - Consolidated Statements of
Cash Flows
28: R7 Note 1 Nature of Operations HTML 23K
21: R8 Note 2 Summary of Significant Accounting Policies HTML 33K
15: R9 Note 3 Going Concern HTML 22K
45: R10 Note 4 Related Party Transactions HTML 25K
35: R11 Note 5 Stockholders' Deficit HTML 29K
34: R12 Note 6 Income Taxes HTML 22K
39: R13 Note 7 Commitments and Contingencies HTML 22K
40: R14 Note 8 Subsequent Events HTML 36K
38: R15 Note 2 Summary of Significant Accounting Policies: HTML 20K
Basis of Presentation (Policies)
41: R16 Note 2 Summary of Significant Accounting Policies: HTML 23K
Principles of Consolidation (Policies)
30: R17 Note 2 Summary of Significant Accounting Policies: HTML 24K
Development Stage Entity (Policies)
32: R18 Note 2 Summary of Significant Accounting Policies: HTML 20K
Use of Estimates (Policies)
37: R19 Note 2 Summary of Significant Accounting Policies: HTML 22K
Cash and Cash Equivalents (Policies)
48: R20 Note 2 Summary of Significant Accounting Policies: HTML 21K
Property and Equipment (Policies)
42: R21 Note 2 Summary of Significant Accounting Policies: HTML 19K
Due To Related Party (Policies)
26: R22 Note 2 Summary of Significant Accounting Policies: HTML 20K
Financial Instruments (Policies)
36: R23 Note 2 Summary of Significant Accounting Policies: HTML 22K
Revenue Recognition (Policies)
27: R24 Note 2 Summary of Significant Accounting Policies: HTML 20K
Advertising Expenses (Policies)
14: R25 Note 2 Summary of Significant Accounting Policies: HTML 24K
Income Taxes (Policies)
43: R26 Note 2 Summary of Significant Accounting Policies: HTML 21K
Stock Based Compensation (Policies)
46: R27 Note 2 Summary of Significant Accounting Policies: HTML 23K
Earnings (loss) Per Share (Policies)
18: R28 Note 2 Summary of Significant Accounting Policies: HTML 19K
Reclassification (Policies)
17: R29 Note 2 Summary of Significant Accounting Policies: HTML 19K
Recent Accounting Pronouncements (Policies)
19: R30 Note 3 Going Concern (Details) HTML 30K
20: R31 Note 4 Related Party Transactions (Details) HTML 24K
22: R32 Note 6 Income Taxes (Details) HTML 27K
13: R33 Note 8 Subsequent Events (Details) HTML 43K
47: XML IDEA XML File -- Filing Summary XML 69K
12: EXCEL IDEA Workbook of Financial Reports XLSX 51K
16: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 113K
6: EX-101.INS XBRL Instance -- dwtp-20141231 XML 149K
8: EX-101.CAL XBRL Calculations -- dwtp-20141231_cal XML 35K
9: EX-101.DEF XBRL Definitions -- dwtp-20141231_def XML 60K
10: EX-101.LAB XBRL Labels -- dwtp-20141231_lab XML 240K
11: EX-101.PRE XBRL Presentations -- dwtp-20141231_pre XML 195K
7: EX-101.SCH XBRL Schema -- dwtp-20141231 XSD 76K
23: ZIP XBRL Zipped Folder -- 0001014897-15-000132-xbrl Zip 32K
| Exhibit 31 |
EXHIBIT 31.1
CERTIFICATION
I, Peter Bloch, certify that:
1.
I have reviewed this annual report on Form 10-K of Bionik Laboratories Corp.;
2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report.
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Annual Report.
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Annual Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on such evaluation; and
d)
Disclosed in this Annual Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
Date:
April 15, 2015
By: /s/ Peter Bloch
Peter Bloch
Principal Executive Officer
EXHIBIT 31.2
CERTIFICATION
I, Leslie Markow, certify that:
1.
I have reviewed this annual report on Form 10-K of Bionik Laboratories Corp.;
2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report.
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Annual Report.
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Annual Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on such evaluation; and
d)
Disclosed in this Annual Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
Date:
April 15, 2015
By: /s/ Leslie Markow
Leslie Markow
Principal Financial and Accounting Officer
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/21/23 Bionik Laboratories Corp. 10-K 3/31/23 78:8.6M Toppan Merrill/FA2 6/09/22 Bionik Laboratories Corp. 10-K 3/31/22 68:7.9M Toppan Merrill/FA2 6/24/21 Bionik Laboratories Corp. 10-K 3/31/21 71:6.3M Toppan Merrill/FA |